Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995)

1991 ◽  
Vol 124 (5) ◽  
pp. 487-491 ◽  
Author(s):  
André Warnet ◽  
Elisabeth Lajeunie ◽  
Françoise Gelbert ◽  
Michèle Duet ◽  
Philippe Chanson ◽  
...  
Keyword(s):  
Adverse Reactions ◽  
Pituitary Tumour ◽  
Somatostatin Analogue ◽  
Line Treatment ◽  
First Line ◽  
Sustained Improvement ◽  
Octreotide Therapy ◽  
Long Acting ◽  
Analogue Octreotide ◽  
First Line Treatment

Abstract. The long-acting somatostatin agonist octreotide can control TSH hypersecretion from most thyrotropic adenomas. Octreotide therapy has even been shown to improve chiasmal dysfunction. We report another patient in whom octreotide therapy was associated with gradual suppression of TSH hypersecretion, which escaped partially, dramatic and very rapid and sustained improvement of chiasm compression, and dramatic and sustained shrinkage of an unresectable TSH-secreting pituitary tumour. Unusual and prolonged gastrointestinal adverse reactions eventually disappeared except for steatorrhea. In conclusion, octreotide may be considered as first line treatment in patients with unresectable thyrotropic adenomas.

Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin®)

1989 ◽  
Vol 121 (1) ◽  
pp. 34-40 ◽  
Author(s):  
C. D. A. Stehouwer ◽  
W. F. Lems ◽  
H. R. A. Fischer ◽  
W. H. L. Hackeng ◽  
M. A. B. Naafs
Keyword(s):  
Blood Glucose ◽  
Hormone Secretion ◽  
Somatostatin Analogues ◽  
Serum Glucose ◽  
Somatostatin Analogue ◽  
Transient Decrease ◽  
Glucoregulatory Hormones ◽  
Octreotide Therapy ◽  
Long Acting ◽  
Analogue Octreotide

Abstract. Recently somatostatin analogues were successfully used to control insulin-induced hypoglycemia in patients with insulinoma. We observed a transient decrease in glucose levels and symptomatic hypoglycemia after administration of the long-acting somatostatin analogue octreotide (Sandostatin®) in two insulinoma patients. We studied the acute effects of octreotide (administered before breakfast) on blood glucose and glucoregulatory hormones in these patients. In one patient, we studied the effects of glucagon replacement and changing the time of breakfast (relative to octreotide administration) on octreotide-associated changes in blood glucose and glucoregulatory hormones. Compared with control levels, octreotide therapy reduced insulin levels. During hypoglycemia glucagon and growth hormone levels were suppressed, but cortisol levels appropriately increased. The increase in catecholamine levels was normal in one patient, but markedly attenuated in the other. A transient decrease in serum glucose after octreotide was absent after glucagon replacement, but present when breakfast was taken before administration of octreotide. We conclude that in patients with insulinoma, octreotide therapy may be associated with clinically important hypoglycemia, during which counterregulatory hormone secretion may be attenuated.

scholarly journals Comparative effectiveness of long-acting antipsychotics: issues and challenges from a pragmatic randomised study

2015 ◽  
Vol 25 (1) ◽  
pp. 21-23 ◽  
Author(s):  
G. Ostuzzi ◽  
C. Barbui
Keyword(s):  
Clinical Practice ◽  
Comparative Effectiveness ◽  
Psychotic Disorders ◽  
Paliperidone Palmitate ◽  
Line Treatment ◽  
First Line ◽  
Haloperidol Decanoate ◽  
Randomised Study ◽  
Long Acting ◽  
First Line Treatment

Although long-acting antipsychotics are widely used in individuals with psychotic disorders, it is unclear which long-acting preparation should be considered as first-line treatment in clinical practice. In this commentary, the main strengths and weaknesses of a recently published pragmatic randomised study comparing long-acting paliperidone palmitate v. long-acting haloperidol decanoate are briefly analysed.

Long-acting injectable antipsychotics: shall the last be first?

CNS Spectrums ◽  
2014 ◽  
Vol 19 (1) ◽  
pp. 3-5 ◽  
Author(s):  
Stephen M. Stahl
Keyword(s):  
Paradigm Shift ◽  
Line Treatment ◽  
First Line ◽  
Long Acting ◽  
First Line Treatment

ISSUE:A paradigm shift is afoot in which the “last shall be first,” namely, use of long-acting injectable (LAI) antipsychotics, rather than being reserved for use only at the last stages of schizophrenia, may be shifting to first-line treatment of early episodes of this illness.

Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update

2020 ◽  
Vol 54 (01) ◽  
pp. 18-22
Author(s):  
Michael Soyka
Keyword(s):  
Clinical Data ◽  
Opioid Dependence ◽  
Maintenance Treatment ◽  
Clinical Implications ◽  
Line Treatment ◽  
Opioid Maintenance Treatment ◽  
First Line ◽  
Depot Formulation ◽  
Long Acting ◽  
First Line Treatment

AbstractOpioid maintenance treatment with oral methadone or sublingual buprenorphine is the first-line treatment in opioid dependence. Three novel long-acting buprenorphine formulations have been approved or will be available soon: for subcutaneous weekly and monthly application, the depot formulations CAM 2038 (Buvidal®), the monthly depot formulation RBP-6000 (Sublocade™), and a 6-month buprenorphine implant (Probuphine™). Clinical data available so far on the efficacy of these 3 medications are given, and possible clinical implications are discussed.

scholarly journals Availability, cost, and affordability of asthma and chronic obstructive pulmonary disease medications in The Gambia

2020 ◽  
Vol 0 ◽  
pp. 1-9
Author(s):  
Baboucarr Sanyang ◽  
Emily Jagne ◽  
Nana Sefa ◽  
Sunkaru Touray
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Fluticasone Propionate ◽  
Pulmonary Disease ◽  
The Gambia ◽  
Chronic Obstructive ◽  
Line Treatment ◽  
First Line ◽  
Obstructive Pulmonary Disease ◽  
Long Acting ◽  
First Line Treatment

Objectives: Guidelines for asthma and chronic obstructive pulmonary disease (COPD) have undergone significant changes. Specifically, inhaled corticosteroids (ICSs) either alone or in combination with a long-acting beta2-agonist (LABA) are now first-line treatment for asthma, while long-acting muscarinic antagonists alone or in combination with LABAs are first-line treatment of COPD. Data on local availability, cost, and affordability of these medicines in The Gambia are unknown. Materials and Methods: We surveyed all registered pharmacists in Gambia and calculated affordability indices relative to the prevailing wage of the lowest government worker. Results: Eight out of 18 registered pharmacists responded to the survey. Respondents were responsible for stocking 19 out 26 registered pharmacies in the country, resulting in a response rate of 44%. Salbutamol inhalers were widely available, stocked by the central medical stores and 6 out of 8 surveyed pharmacists. Only one pharmacist reported stocking beclometasone 50 mcg, budesonide 100 mcg, and fluticasone propionate 125 mcg inhalers. Aminophylline was stocked by 4/8 pharmacists. The price of salbutamol 100 mcg inhaler was Gambian Dalasi (GMD) 200 (US$ 4, 4 days’ wages), while ipratropium bromide 20 mcg cost GMD 675 (US$ 14, 15 days’ wages). ICS maintenance inhalers at private pharmacies cost 15, 26, and 28 days’ wages for beclomethasone 50 mcg, fluticasone propionate 125 mcg, and budesonide 100 mcg, respectively. Combination of ICS/LABA inhaler was 26 days’ wages while tiotropium bromide 18 mcg affordability was 95 days’ wages. Conclusion: Guideline recommended medications for the management of asthma and COPD in The Gambia are unavailable, expensive, and unaffordable.

scholarly journals Efficacy and safety of bevacizumab in combination with irinotecan and capecitabine in first-line treatment of metastatic colorectal carcer

2017 ◽  
Vol 74 (3) ◽  
pp. 249-255
Author(s):  
Sasa Jungic ◽  
Biljana Tubic ◽  
Radoslav Gajanin ◽  
Zdenka Gojkovic ◽  
Ivanka Rakita
Keyword(s):  
Adverse Effects ◽  
Adverse Reactions ◽  
Progressive Disease ◽  
Overall Response Rate ◽  
Line Treatment ◽  
Efficacy And Safety ◽  
First Line ◽  
First Line Therapy ◽  
Hand Foot Syndrome ◽  
First Line Treatment

Background/Aim. The efficacy and safety of bevacizumab (BEV) in combination with capecitabin and irinotecan in first-line therapy for patients with metastatic colorectal cancer (mCRC) were studied. In order to improve safety and efficacy of chemotherapy, as well as to reduce adverse reactions to a minimum, doses of active agents applied were changed in relation to previously employed schedules. Methods. Patients with histologically documented mCRC with no previously received chemotherapy or with received adjuvant or neoadjuvant chemotherapy, which ended 6 months before capecitabin treatment (1000 mg/m2 per os from the 2nd to 8th day of each cycle), irinotecan (175 mg/m2 iv every 2 weeks), plus bevacizumab (5 mg/kg iv every 2 weeks) were observed. Results. This prospective study included 35 patients of both sexes. The overall response rate (ORR) of 28.6%, partial response (PR) of 28.6%, progressive disease (PD) of 28.6% and stable disease (SD) of 42.8% were found. The progressionfree survival (PFS) of the analyzed patients was 11.3 (95% CL: 9.1?12.9) months while overall survival (OS) of the included patients was 25.2 (95% CL: 17.4?28.4) months and 117 adverse effects were recorded in 24 patients. Alopecia, nausea and vomiting, hemorrhage, hand-foot syndrome, diarrhea, abdominal pain, proteinuria, and hypertension (51.4%, 37.1%, 37.1%, 25.7%, 22.8%, 20.0%, 20.0% and 17.1%, respectively) were most frequently observed adverse effects. Conclusion. The results of this clinical trial support and recommend the use of bevacizumab plus capecitabin and irinotecan in the doses and schedule applied throughout this study as the first-line treatment of mCRC patients.

Sign in / Sign up

Export Citation Format

Share Document